In a significant advancement for non-small cell lung cancer (NSCLC) treatment, Akeso and Summit Therapeutics have revealed astounding results from their phase 3 HARMONi-2 trial. Ivonescimab, a PD-1/VEGF bispecific antibody, has demonstrated remarkable efficacy against Merck’s Keytruda, positioning i
BlueRock Therapeutics, a cell therapy company under Bayer, has recently announced FDA clearance for its Investigational New Drug (IND) application for OpCT-001. This investigational induced pluripotent stem cell (iPSC)-derived therapy aims to treat primary photoreceptor diseases, which are a
Rentschler Biopharma has recently unveiled an innovative lentiviral vector (LVV) manufacturing toolbox at its advanced therapies site in Stevenage, United Kingdom, significantly enhancing its service offerings in the gene therapy sector. This strategic expansion complements their established
In the evolving landscape of cancer treatment, the advent of immunotherapies Keytruda and Opdivo has marked a groundbreaking shift. Over the last decade, these drugs, known as PD1 inhibitors, have revolutionized oncology, offering new hope and significantly altering patient outcomes. Their story is
Arsenal Biosciences, commonly known as ArsenalBio, has achieved a remarkable milestone by securing $325 million in a Series C funding round. This significant financial boost arrives amid a challenging year for biotech investments, particularly in the cell and gene therapy sectors. The raised
Sanofi, a leading pharmaceutical company, recently announced the results of its clinical trials for tolebrutinib, an experimental drug targeting multiple sclerosis (MS). The mixed outcomes have generated a buzz within the medical and investment communities. While the drug did not outperform an
